Cretostimogene grenadenorepvec in combination with pembrolizumab produced high complete response rates with a tolerable safety profile in patients with Bacillus Calmette-Guérin–unresponsive non–muscle invasive bladder cancer.
Arquer Diagnostics ADXBLADDER Becomes First Bladder Cancer Urine Test To Undergo Rigorous Clinical Trials In USA First patients recruited for bladder cancer recurrence monitoring study News provided by Share this article SUNDERLAND, England, July 27, 2021 /PRNewswire/ ADXBLADDER has become the first new generation urinary biomarker test for bladder cancer to undergo rigorous clinical trials in the USA in decades. The innovative and highly accurate test, developed by UK company Arquer Diagnostics, is already approved for use across Europe. ADXBLADDER is now being evaluated in a bladder cancer recurrence monitoring study in the US. With results of the study expected by the end of 2021, Arquer Diagnostics hopes to make a 510(k) premarket submission to the US Food and Drug Administration (FDA) to gain clearance from the organisation for
Survey finds misdiagnosis and delays putting women's lives at risk SUNDERLAND, England, May 6, 2021 /PRNewswire/ Women with bladder cancer symptoms feel ignored by their doctor, face
New Hope For Women With Suspected Endometrial Cancer As Arquer Diagnostics' Innovative Urine Test Rules Out Disease In Up To 99% Of Cases prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.